New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for bacillus anthracis

Current Medicinal Chemistry

Volumn 18, Issue 33, 2011, Pages 5083-5094

  Beierlein, J M ^a   Anderson, A C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Anthrax toxins; Antibiotics; B. anthracis; Biodefense; Edema factor; Inhalation anthrax; Lethal factor; Resistance; Structure based drug design; Vaccines

Indexed keywords

ANTHRAX TOXIN; ANTIBIOTIC AGENT; VACCINE;

ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PURITY; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; VACCINATION;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 80054867025     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797636036     Document Type: Article

References (146)

1. Prevention, C.f.D.C.a. Biological and chemical terrorism: Strategic plan for preparedness and response. Morb Mortal Wkly Rep, 2000, 49, (RR-4), 1-14.
2. Tournier, J.-N.; Rossi Paccani, S.; Quesnel-Hellmann, A.; Baldari, C.T. Anthrax toxins: A weapon to systematically dismantle the host immune defenses. Mol. Aspects Med., 2009, 30, (6), 456-466.
3. Mock, M.; Fouet, A., Anthrax. Ann. Rev. Micro., 2001, 55, (1), 647.
4. Bouzianas, D.G. Current and Future Medical Approaches To Combat the Anthrax Threat. J. Med. Chem., 2010, 53, 4305-4331.
5. Driks, A. The Bacillus anthracis spore. Mol. Aspects Med., 2009, 30, 368-373.
6. Jon, E.; Holty, C.; Bravata, D.M.; Hau, L.; Olshen, R.A.; McDonald, K.M.; Owens, D.K. Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005. Annals of Internal Medicine, 2006, 144, 270-W254.
7. Duesbery, N.S.; Vande, W.G.F. Anthrax toxins. Cell. Mol. Life Sci., 1999, 55, 1599-1609. (Pubitemid 29445825)
8. Kolstø, A.-B.; Tourasse, N.J.; Økstad, O.A. What Sets Bacillus anthracis Apart from Other Bacillus Species? Ann. Rev. Micro., 2009, 63, 451-476.
9. Keim, P.; Gruendike, J.M.; Klevytska, A.M.; Schupp, J.M.; Challacombe, J.; Okinaka, R. The genome and variation of Bacillus anthracis. Mol. Aspects Med., 2009, 30, 397-405.
10. Fouet, A. The surface of Bacillus anthracis. Mol. Aspects Med., 2009, 30, 374-385.
11. Fouet, A. AtxA, a Bacillus anthracis global virulence regulator. Research in Microbiology, 2010, 161, 735-742.
12. Fritze, D. Taxonomy of the genus bacillus and related genera: The aerobic endospore-forming bacteria. Phytopathology, 2004, 94, 1245-1248. (Pubitemid 39448203)
13. Gillissen, G. Handbook Exp. Pharmakol. 11A ed., 1967; 16, 291-342.
14. Uchida, I.; Hashimoto, K.; Terakado, N. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids. J Gen Microbiol, 1986, 132, 557-559. (Pubitemid 16123870)
15. Okinaka, R.T.; Cloud, K.; Hampton, O.; Hoffmaster, A.R.; Hill, K.K.; Keim, P.; Koehler, T.M.; Lamke, G.; Kumano, S.; Mahillon, J.; Manter, D.; Martinez, Y.; Ricke, D.; Svensson, R.; Jackson, P.J. Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J. Bacteriol., 1999, 181, 6509-6515. (Pubitemid 29512963)
16. Mikesell, P.; Ivins, B.E.; Ristroph, J.D.; Dreier, T.M. Evidence for plasmidmediated toxin production in Bacillus anthracis. Infect. Immun., 1983, 39, 371-376. (Pubitemid 13212538)
17. Duesbery, N.S.; Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Marianne, M.K.; Fukasawa, K.; Paull, K.D.; Vande, W.G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science, 1998, 280, 734-737. (Pubitemid 28243347)
18. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNβ-induced release of NO and TNF. FEBS Lett., 1999, 462, 199-204.
19. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun., 1998, 248, 706-711. (Pubitemid 28404486)
20. Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J., 2000, 352, 739-745. (Pubitemid 32015030)
21. Chopra, A.P.; Boone, S.A.; Liang, X.; Duesbery, N.S. Anthrax Lethal Factor Proteolysis and Inactivation of MAPK Kinase. J. Biol. Chem., 2003, 278, 9402-9406. (Pubitemid 36800429)
22. Turk, B.E. Manipulation of host signaling pathways by anthrax toxins. Biochem. J., 2007, 402, 405-417. (Pubitemid 46423878)
23. Leppla, S.H. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A., 1982, 79, 3162-3166. (Pubitemid 12008374)
24. Laine, E.; Martinez, L.; Blondel, A.; Malliavin, T.E, Activation of the Edema Factor of Bacillus anthracis by Calmodulin: Evidence of an Interplay between the EF-Calmodulin Interaction and Calcium Binding. Biophys. J., 2010, 99, 2264-2272.
25. Tang, W.-J.; Guo, Q. The adenylyl cyclase activity of anthrax edema factor. Mol. Aspects Med., 2009, 30, 423-430.
26. Klimpel, K.R.; Molloy, S.S.; Thomas, G.; Leppla, S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 10277-10281.
27. Bradley, K.A.; Mogrfdge, J.; Mourez, M.; Collier, R.J.; Young, J.A.T. Identification of the cellular receptor for anthrax toxin. Nature, 2001, 414, 225-229. (Pubitemid 33051239)
28. Elliott, J.L.; Mogridge, J.; Collier, R.J. A Quantitative Study of the Interactions of Bacillus anthracis Edema Factor and Lethal Factor with Activated Protective Antigen. Biochemistry, 2000, 39, 6706-6713. (Pubitemid 30354003)
29. Mogridge, J.; Cunningham, K.; Collier, R.J. Stoichiometry of Anthrax Toxin Complexes. Biochemistry, 2002, 41, 1079-1082. (Pubitemid 34065284)
30. Abrami, L.; Liu, S.; Cosson, P.; Leppla, S.H.; van, d.G.F.G. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrindependent process. J. Cell Biol., 2003, 160, 321-328. (Pubitemid 36182723)
31. Pimental, R.-A.L.; Christensen, K.A.; Krantz, B.A.; Collier, R.J. Anthrax toxin complexes: Heptameric protective antigen can bind lethal factor and edema factor simultaneously. Biochem. Biophys. Res. Commun., 2004, 322, 258-262. (Pubitemid 39093863)
32. Petosa, C.; Collier, R.J.; Klimpel, K.R.; Leppla, S.H.; Liddington, R.C. Crystal structure of the anthrax toxin protective antigen. Nature, 1997, 385, 833-838. (Pubitemid 27106075)
33. Katayama, H.; Wang, J.; Tama, F.; Chollet, L.; Gogol, E.P.; Collier, R.J.; Fisher, M.T. Three-dimensional structure of the anthrax toxin pore inserted into lipid nanodiscs and lipid vesicles. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 3453-3457.
34. Cai, C.; Zhao, Y.; Tong, X.; Fu, S.; Li, Y.; Wu, Y.; Li, X.; Lou, Z. Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1. Acta Crystallogr., 2011, F67, 64-67.
35. Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Blenkowska, J.; Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; Hanna, P.; Liddington, R.C. Crystal structure of the anthrax lethal factor. Nature, 2001, 414, 229-233. (Pubitemid 33051240)
36. Collier, R.J. Membrane translocation by anthrax toxin. Mol. Aspects Med., 2009, 30, 413-422.
37. Lacy, D.B.; Wigelsworth, D.J.; Melnyk, R.A.; Harrison, S.C.; Collier, R.J. Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 13147-13151. (Pubitemid 39209633)
38. Shen, Y.; Zhukovskaya, N.L.; Guo, Q.; Florian, J.; Tang, W.-J. Calciumindependent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J., 2005, 24, 929-941. (Pubitemid 40470142)
39. Turnbull, P.C.; Hutson, R.A.; Ward, M.J.; Jones, M.N.; Quinn, C.P.; Finnie, N.J.; Duggleby, C.J.; Kramer, J.M.; Melling, J. Bacillus anthracis but not always anthrax. J Appl Bacteriol, 1992, 72, 21-28. (Pubitemid 23396962)
40. Green, B.D.; Battisti, L.; Koehler, T.M.; Thorne, C.B.; Ivins, B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun., 1985, 49, 291-297. (Pubitemid 15004855)
41. Drysdale, M.; Heninger, S.; Hutt, J.; Chen, Y.; Lyons, C.R.; Koehler, T.M. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J., 2005, 24, 221-227. (Pubitemid 40188479)
42. Hambleton, P.; Carman, J.A.; Melling, J. Anthrax: The disease in relation to vaccines. Vaccine, 1984, 2, 125-132. (Pubitemid 14050772)
43. Cataldi, A.; Mock, M.; Bentancor, L. Characterization of Bacillus anthracis strains used for vaccination. J. Appl. Microbiol., 2000, 88, 648-654. (Pubitemid 30224978)
44. Sterne, M. Avirulent anthrax vaccine. Onderstepoort J Vet Sci Anim Ind, 1946, 21, 41-43.
45. Dixon, T.C.; Meselson, M.; Guillemin, J.; Hanna, P.C. Anthrax. N Engl J Med, 1999, 341, 815-826.
46. Swartz, M.N. Recognition and management of anthrax-an update. N Engl J Med, 2001, 345, 1621-1626.
47. Inglesby, T.V.; O'Toole, T.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Friedlander, A.M.; Gerberding, J.; Hauer, J.; Hughes, J.; McDade, J.; Osterholm, M.T.; Parker, G.; Perl, T.M.; Russell, P.K.; Tonat, K. For the Working Group on Civilian Biodefense, Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management. JAMA, 2002, 287, 2236-2252. (Pubitemid 34441940)
48. Aksaray, N.; Cinaz, P.; Coskun, U.; Serbest, M.; Koksal, F. Cutaneous anthrax. Trop Geogr Med, 1990, 42, 168-171. (Pubitemid 20342003)
49. Spencer, R.C. Bacillus anthracis. J Clin Pathol, 2003, 56, 182-187. (Pubitemid 36308031)
50. Zilinskas, R.A. Iraq's biological weapons. The past as future? JAMA, 1997, 278, 418-424. (Pubitemid 27327461)
51. Meselson, M.; Guillemin, J.; Hugh-Jones, M.; Langmuir, A.; Popova, I.; Shelokov, A.; Yampolskaya, O. The sverdlovsk anthrax outbreak of 1979. Science, 1994, 266, 1202-1208. (Pubitemid 24371272)
52. Abramova, F.A.; Grinberg, L.M.; Yampolskaya, O.V.; Walker, D.H. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A, 1993, 90, 2291-2294. (Pubitemid 23078612)
53. Keim, P.; Smith, K.L.; Keys, C.; Takahashi, H.; Kurata, T.; Kaufmann, A. Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J. Clin. Microbiol., 2001, 39, 4566-4567. (Pubitemid 33117163)
54. Anonymous, Update: Investigation of bioterrorism-related anthrax- Connecticut, 2001. MMWR Morb Mortal Wkly Rep, 2001, 50, 1077-1079.
55. Jernigan, J.A.; Stephens, D.S.; Ashford, D.A.; Omenaca, C.; Topiel, M.S.; Galbraith, M.; Tapper, M.; Fisk, T.L.; Zaki, S.; Popovic, T.; Meyer, R.F.; Quinn, C.P.; Harper, S.A.; Fridkin, S.K.; Sejvar, J.J.; Shepard, C.W.; McConnell, M.; Guarner, J.; Shieh, W.J.; Malecki, J.M.; Gerberding, J.L.; Hughes, J.M.; Perkins, B.A. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis, 2001, 7, 933-944. (Pubitemid 33115771)
56. Bush, L.M.; Abrams, B.H.; Beall, A.; Johnson, C.C. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med, 2001, 345, 1607-1610. (Pubitemid 33126840)
57. Price, L.B.; Vogler, A.; Pearson, T.; Busch, J.D.; Schupp, J.M.; Keim, P. In vitro selection and characterization of Bacillus anthracis mutants with highlevel resistance to ciprofloxacin. Antimicrob. Agents Chemother., 2003, 47, 2362-2365. (Pubitemid 36753604)
58. Athamna, A.; Athamna, M.; Abu-Rashed, N.; Medlej, B.; Bast, D.J.; Rubinstein, E. Selection of Bacillus anthracis isolates resistant to antibiotics. J. Antimicrob. Chemother., 2004, 54, 424-428. (Pubitemid 39177464)
59. Brook, I.; Elliott, T.B.; Pryor, H.I.; Sautter, T.E.; Gnade, B.T.; Thakar, J.H.; Knudson, G.B. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents, 2001, 18, 559-562. (Pubitemid 33152750)
60. Choe, C.H.; Bouhaouala, S.S.; Brook, I.; Elliott, T.B.; Knudson, G.B. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis sterne. Antimicrob. Agents Chemother., 2000, 44, 1766. (Pubitemid 30340839)
61. Stepanov, A.V.; Marinin, L.I.; Pomerantsev, A.P.; Staritsin, N.A. Development of novel vaccines against anthrax in man. J. Biotechnol., 1996, 44, 155-160. (Pubitemid 26056574)
62. Jefferds, M.D.; Laserson, K.; Fry, A.M.; Roy, S.; Hayslett, J.; Grummer- Strawn, L.; Kettel-Khan, L.; Schuchat, A. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis, 2002, 8, 1138-1144. (Pubitemid 35257007)
63. Wein, L.M.; Craft, D.L.; Kaplan, E.H. Emergency response to an anthrax attack. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 4346-4351. (Pubitemid 36418205)
64. Shlyakhov, E.N.; Rubinstein, E. Human live anthrax vaccine in the former USSR. Vaccine, 1994, 12, 727-730. (Pubitemid 24182373)
65. BioThrax (anthrax vaccine adsorbed). [Vaccine package insert], 2008.
66. Weiss, M.M.; Weiss, P.D.; Weiss, J.B. Anthrax vaccine and public health policy. Am J Public Health, 2007, 97, 1945-1951.
67. Joellenbeck, L.M.; Durch, J.S.; Strom, B.L. The Anthrax Vaccine: Is It Safe? Does It Work? National Academies Press: Washington, D.C., 2002.
68. Turnbull, P.C.B. Current status of immunization against anthrax: Old vaccines may be here to stay for a while. Curr. Op. Infect. Dis., 2000, 13, 113-120. (Pubitemid 30223744)
69. Friedlander, A.M.; Welkos, S.L.; Pitt, M.L.; Ezzell, J.W.; Worsham, P.L.; Rose, K.J.; Ivins, B.E.; Lowe, J.R.; Howe, G.B.; Mikesell, P.; et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis, 1993, 167, 1239-1243. (Pubitemid 23115626)
70. Vietri, N.J.; Purcell, B.K.; Lawler, J.V.; Leffel, E.K.; Rico, P.; Gamble, C.S.; Twenhafel, N.A.; Ivins, B.E.; Heine, H.S.; Sheeler, R.; Wright, M.E.; Friedlander, A.M. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 7813-7816.
71. Crowe, S.R.; Ash, L.L.; Engler, R.J.M.; Ballard, J.D.; Harley, J.B.; Farris, A.D.; James, J.A. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J. Infect. Dis., 2010, 202, 251-260.
72. Oscherwitz, J.; Yu, F.; Cease, K.B. A Synthetic Peptide Vaccine Directed against the 22-23 Loop of Domain 2 of Protective Antigen Protects Rabbits from Inhalation Anthrax. J. Immunol., 2010, 185, 3661-3668.
73. Migone, T.-S.; Subramanian, M.; Zhong, J.; Healey, L.M.; Corey, A.; Devalaraja, M.; Lo, L.; Ullrich, S.; Zimmerman, J.; Chen, A.; Lewis, M.; Meister, G.; Gillum, K.; Sanford, D.; Mott, J.; Bolmer, S.D. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med., 2009, 361, 135-144.
74. Antoniu, S.A. Raxibacumab for inhalational anthrax: An effective specific therapeutic approach? Expert Opinion on Investigational Drugs, 2010, 19, 909-911.
75. Adusumilli, S. Raxibacumab: Treatment of anthrax infection. Drugs Future, 2010, 35, 179-182.
76. Anonymous, Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep, 2001, 50, 909-919.
77. Barnes, J.M. Penicillin and Bacillus anthracis. J. Pathol. Bacteriol., 1947, 59, 113-125.
78. Kelly, D.J.; Chulay, J.D.; Mikesell, P.; Friedlander, A.M. Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J. Infect. Dis., 1992, 166, 1184-1187.
79. Odendaal, M.W.; Pieterson, P.M.; de, V.V.; Botha, A.D. The antibiotic sensitivity patterns of Bacillus anthracis isolated from the Kruger National Park. Onderstepoort J Vet Res, 1991, 58, 17-19.
80. Doganay, M.; Aydin, N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis, 1991, 23, 333-335.
81. Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Friedlander, A.M.; Hauer, J.; McDade, J.; Osterholm, M.T.; O'Toole, T.; Parker, G.; Perl, T.M.; Russell, P.K.; Tonat, K. Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA, 1999, 281, 1735-1745. (Pubitemid 29226485)
82. Heine, H.S.; Bassett, J.; Miller, L.; Purcell, B.K.; Byrne, W.R. Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob. Agents Chemother., 2010, 54, 4471-4473.
83. Heine, H.S.; Purcell, B.K.; Bassett, J.; Miller, L.; Goldstein, B.P. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob. Agents Chemother., 2010, 54, 991-996.
84. Gill, S.C.; Rubino, C.M.; Bassett, J.; Miller, L.; Ambrose, P.G.; Bhavnani, S.M.; Beaudry, A.; Li, J.; Stone, K.C.; Critchley, I.; Janjic, N.; Heine, H.S. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob. Agents Chemother., 2010, 54, 1678-1683.
85. Gold, H. Treatment of anthrax. Fed Proc, 1967, 26, 1563-1568.
86. Vietri, N.J.; Purcel, B.K.; Tobery, S.A.; Rasmussen, S.L.; Leffel, E.K.; Twenhafel, N.A.; Ivins, B.E.; Kellogg, M.D.; Webster, W.M.; Wright, M.E.; Friedlander, A.M. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J. Infect. Dis., 2008, 199, 336-341.
87. Brey, R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Delivery Rev., 2005, 57, 1266-1292. (Pubitemid 40796126)
88. Wang, J.Y.; Roehrl, M.H. Anthrax vaccine design: Strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol., 2005, 4.
89. Baillie, L.W. Is new always better than old? The development of human vaccines for anthrax. Hum. Vaccines, 2009, 5, 806-816.
90. Friedlander, A.M.; Little, S.F. Advances in the development of nextgeneration anthrax vaccines. Vaccine, 2009, 27, D28-D32.
91. Friedlander, A.M.; Little, S.F.; Gurwith, M. Informa Healthcare, 2010, 851-863.
92. Chitlaru, T.; Altboum, Z.; Reuveny, S.; Shafferman, A. Progress and novel strategies in vaccine development and treatment of anthrax. Immunological Reviews, 2011, 239, 221-236.
93. Brachman, P.S.; Gold, H.; Plotkin, S.A.; Fekety, F.R.; Werrin, M.; Ingraham, N.R. Field Evaluation of a Human Anthrax Vaccine. Am J Public Health Nations Health, 1962, 52, 632-645.
94. Klinman, D.M.; Xie, H.; Ivins, B.E. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann. N. Y. Acad. Sci., 2006, 1082, 137-150. (Pubitemid 44955459)
95. Ivins, B.E.; Welkos, S.L.; Little, S.F.; Crumrine, M.H.; Nelson, G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun., 1992, 60, 662-668.
96. Mohamed, N.; Li, J.; Ferreira, C.S.; Little, S.F.; Friedlander, A.M.; Spitalny, G.L.; Casey, L.S. Enhancement of anthrax lethal toxin cytotoxicity: A subset of monoclonal antibodies against protective antigen increases lethal toxinmediated killing of murine macrophages. Infect. Immun., 2004, 72, 3276-3283. (Pubitemid 38697749)
97. Abboud, N.; Casadevall, A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin. Vaccine Immunol., 2008, 15, 1115-1123. (Pubitemid 352018319)
98. Baillie, L.W.; Huwar, T.B.; Moore, S.; Mellado-Sanchez, G.; Rodriguez, L.; Neeson, B.N.; Flick-Smith, H.C.; Jenner, D.C.; Atkins, H.S.; Ingram, R.J.; Altmann, D.M.; Nataro, J.P.; Pasetti, M.F. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine, 2010, 28, 6740-6748.
99. Wycoff, K.L.; Belle, A.; Deppe, D.; Schaefer, L.; MacLean, J.M.; Haase, S.; Trilling, A.K.; Liu, S.; Leppla, S.H.; Geren, I.N.; Pawlik, J.; Peterson, J.W. Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax. Antimicrob. Agents Chemother., 2011, 55, 132-139.
100. Taft, S.C.; Weiss, A.A. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol., 2008, 15, 71-75. (Pubitemid 351966536)
101. Brown, B.K.; Cox, J.; Gillis, A.; Van, C.T.C.; Marovich, M.; Milazzo, M.; Antonille, T.S.; Wieczorek, L.; McKee, K.T., Jr.; Metcalfe, K.; Mallory, R.M.; Birx, D.; Polonis, V.R.; Robb, M.L. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One, 2010, 5, e13849.
102. Campbell, J.D.; Clement, K.H.L.; Wasserman, S.S.; Donegan, S.; Chrisley, L.; Kotloff, K.L., Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin, 2007, 3, 205-211. (Pubitemid 47598179)
103. Wang, S.H.; Kirwan, S.M.; Abraham, S.N.; Staats, H.F.; Hickey, A.J. Stable dry powder formulation for nasal delivery of anthrax vaccine. J. Pharm. Sci., in press.
104. Merkel, T.J.; Perera, P.-Y.; Kelly, V.K.; Verma, A.; Llewellyn, Z.N.; Waldmann, T.A.; Mosca, J.D.; Pererad, L.P. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 18091-18096.
105. Karginov, V.A.; Nestorovich, E.M.; Schmidtmann, F.; Robinson, T.M.; Yohannes, A.; Fahmi, N.E.; Bezrukov, S.M.; Hecht, S.M. Inhibition of S. aureus β-hemolysin and B. anthracis lethal toxin by β-cyclodextrin derivatives. Bioorg. Med. Chem., 2007, 15, 5424-5431. (Pubitemid 46963000)
106. Karginov, V.A.; Yohannes, A.; Robinson, T.M.; Fahmi, N.E.; Alibek, K.; Hecht, S.M. β-Cyclodextrin derivatives that inhibit anthrax lethal toxin. Bioorg. Med. Chem., 2006, 14, 33-40. (Pubitemid 41635466)
107. Karginov, V.A.; Nestorovich, E.M.; Yohannes, A.; Robinson, T.M.; Fahmi, N.E.; Schmidtmann, F.; Hecht, S.M.; Bezrukov, S.M. Search for cyclodextrin-based inhibitors of anthrax toxins: Synthesis, structural features, and relative activities. Antimicrob. Agents Chemother., 2006, 50, 3740-3753. (Pubitemid 44684889)
108. Moayeri, M.; Robinson, T.M.; Leppla, S.H.; Karginov, V.A. In vivo efficacy of β-cyclodextrin derivatives against anthrax lethal toxin. Antimicrob. Agents Chemother., 2008, 52, 2239-2241. (Pubitemid 351758567)
109. Karginov, V.A.; Nestorovich, E.M.; Moayeri, M.; Leppla, S.H.; Bezrukov, S.M. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 15075-15080. (Pubitemid 41513337)
110. Nestorovich, E.M.; Karginov, V.A.; Berezhkovskii, A.M.; Bezrukov, S.M. Blockage of Anthrax PA63 Pore by a Multicharged High-Affinity Toxin Inhibitor. Biophys. J., 2010, 99, 134-143.
111. Drum, C.L.; Yan, S.-Z.; Bardt, J.; Shen, Y.-Q.; Lu, D.; Soelalman, S.; Grabarek, Z.; Bohnm, A.; Tang, W.-J. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature, 2002, 415, 396-402. (Pubitemid 34100945)
112. Guo, Q.; Shen, Y.; Zhukovskaya, N.L.; Florian, J.; Tang, W.-J. Structural and Kinetic Analyses of the Interaction of Anthrax Adenylyl Cyclase Toxin with Reaction Products cAMP and Pyrophosphate. J. Biol. Chem., 2004, 279, 29427-29435. (Pubitemid 38915822)
113. Shen, Y.; Zhukovskaya, N.L.; Zimmer, M.I.; Soelaiman, S.; Bergson, P.; Wang, C.-R.; Gibbs, C.S.; Tang, W.-J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 3242-3247. (Pubitemid 38327765)
114. Shen, Y.; Guo, Q.; Zhukovskaya, N.L.; Drum, C.L.; Bohm, A.; Tang, W.-J. Structure of anthrax edema factor-calmodulin-adenosine 5'-(α,β- methylene)- triphosphate complex reveals an alternative mode of ATP binding to the catalytic site. Biochem. Biophys. Res. Commun., 2004, 317, 309-314.
115. Taha, H.M.; Schmidt, J.; Goettle, M.; Suryanarayana, S.; Shen, Y.; Tang, W.-J.; Gille, A.; Geduhn, J.; Koenig, B.; Dove, S.; Seifert, R. Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol. Pharmacol., 2009, 75, 693-703.
116. Laine, E.; Goncalves, C.; Karst, J.C.; Lesnard, A.; Rault, S.; Tang, W.-j.; Malliavin, T.E.; Ladant, D.; Blondel, A. Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 11277-11282.
117. Dalkas, G.A.; Papakyriakou, A.; Vlamis-Gardikas, A.; Spyroulias, G.A. Low molecular weight inhibitors of the protease anthrax lethal factor. Mini-Rev. Med. Chem., 2008, 8, 290-306. (Pubitemid 351611831)
118. Turk, B.E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr. Pharm. Biotechnol., 2008, 9, 24-33. (Pubitemid 351266967)
119. Tonello, F.; Montecucco, C. The anthrax lethal factor and its MAPK kinasespecific metalloprotease activity. Molecular Aspects of Medicine, 2009, 30, 431-438.
120. Shoop, W.L.; Xiong, Y.; Wiltsie, J.; Woods, A.; Guo, J.; Pivnichny, J.V.; Felcetto, T.; Michael, B.F.; Bansal, A.; Cummings, R.T.; Cunningham, B.R.; Friedlander, A.M.; Douglas, C.M.; Patel, S.B.; Wisniewski, D.; Scapin, G.; Salowe, S.P.; Zaller, D.M.; Chapman, K.T.; Scolnick, E.M.; Schmatz, D.M.; Bartizal, K.; MacCoss, M.; Hermes, J.D. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 7958-7963. (Pubitemid 40781045)
121. Dell'Aica, I.; Dona, M.; Tonello, F.; Piris, A.; Mock, M.; Montecucco, C.; Garbisa, S. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep., 2004, 5, 418-422. (Pubitemid 38618286)
122. Fridman, M.; Belakhov, V.; Lee, L.V.; Liang, F.-S.; Wong, C.-H.; Baasov, T. Dual effect of synthetic amino-glycosides: Antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor. Angew. Chem., Int. Ed., 2005, 44, 447-452. (Pubitemid 40138354)
123. Roy, J.; Kumar, U.C.; Machiraju, P.K.; Muttineni, R.K.; Kumar, B.V.S.S.; Gundla, R.; Dayam, R.; Sarma, J.A.R.P. Insilico studies on anthrax lethal factor inhibitors: Pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer. J. Mol. Graphics Modell., 2010, 29, 256-265.
124. Zakharova, M.Y.; Kuznetsov, N.A.; Dubiley, S.A.; Kozyr, A.V.; Fedorova, O.S.; Chudakov, D.M.; Knorre, D.G.; Shemyakin, I.G.; Gabibov, A.G.; Kolesnikov, A.V. Substrate Recognition of Anthrax Lethal Factor Examined by Combinatorial and Pre-steady-state Kinetic Approaches. J. Biol. Chem., 2009, 284, 17902-17913.
125. Muehlbauer, S.M.; Lima, H., Jr.; Goldman, D.L.; Jacobson, L.S.; Rivera, J.; Goldberg, M.F.; Palladino, M.A.; Casadevall, A.; Brojatsch, J. Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin. Am. J. Pathol., 2010, 177, 735-743.
126. Tipparaju, S.K.; Mulhearn, D.C.; Klein, G.M.; Chen, Y.; Tapadar, S.; Bishop, M.H.; Yang, S.; Chen, J.; Ghassemi, M.; Santarsiero, B.D.; Cook, J.L.; Johlfs, M.; Mesecar, A.D.; Johnson, M.E.; Kozikowski, A.P. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase. ChemMedChem, 2008, 3, 1250-1268.
127. Torrents, E.; Sjoeberg, B.-M. Antibacterial activity of radical scavengers against class Ib ribonucleotide reductase from Bacillus anthracis. Biol. Chem., 2010, 391, 229-234.
128. Guimaraes, A.P.; Oliveira, A.A.; da, C.E.F.F.; Ramalho, T.C.; Franca, T.C.C. Design of new chemotherapeutics against the deadly anthrax disease. Docking and molecular dynamics studies of inhibitors containing pyrrolidine and riboamidrazone rings on nucleoside hydrolase from Bacillus anthracis. J. Biomol. Struct. Dyn., 2011, 28, 455-469.
129. Aiello, D.; Barnes, M.H.; Biswas, E.E.; Biswas, S.B.; Gu, S.; Williams, J.D.; Bowlin, T.L.; Moir, D.T. Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg. Med. Chem., 2009, 17, 4466-4476.
130. Gedi, V.; Jayaraman, K.; Kalme, S.; Park, H.-Y.; Park, H.-C.; La, I.-J.; Hahn, H.-G.; Yoon, M.-Y., Evaluation of substituted triazol-1-yl-pyrimidines as inhibitors of Bacillus anthracis acetohydroxyacid synthase. Biochim. Biophys. Acta, Proteins Proteomics, 2010, 1804, 1369-1375.
131. Moro, W.B.; Yang, Z.; Kane, T.A.; Zhou, Q.; Harville, S.; Brouillette, C.G.; Brouillette, W.J. SAR studies for a new class of antibacterial NAD biosynthesis inhibitors. J. Comb. Chem., 2009, 11, 617-625.
132. Huang, N.; Kolhatkar, R.; Eyobo, Y.; Sorci, L.; Rodionova, I.; Osterman, A.L.; MacKerell, A.D.; Zhang, H. Complexes of Bacterial Nicotinate Mononucleotide Adenylyltransferase with Inhibitors: Implication for Structure-Based Drug Design and Improvement. J. Med. Chem., 2010, 53, 5229-5239.
133. Sorci, L.; Pan, Y.; Eyobo, Y.; Rodionova, I.; Huang, N.; Kurnasov, O.; Zhong, S.; MacKerell, A.D.; Zhang, H.; Osterman, A.L. Targeting NAD Biosynthesis in Bacterial Pathogens: Structure-Based Development of Inhibitors of Nicotinate Mononucleotide Adenylyltransferase NadD. Chem. Biol., 2009, 16, 849-861.
134. Morgunova, E.; Illarionov, B.; Saller, S.; Popov, A.; Sambaiah, T.; Bacher, A.; Cushman, M.; Fischer, M.; Ladenstein, R. Structural study and thermodynamic characterization of inhibitor binding to lumazine synthase from Bacillus anthracis. Acta Crystallogr., 2010, D66, 1001-1011.
135. Foss, M.H.; Weibel, D.B. Oligochlorophens are potent inhibitors of Bacillus anthracis. Antimicrob. Agents Chemother., 2010, 54, 3988-3990.
136. Qi, J.; Virga, K.G.; Das, S.; Zhao, Y.; Yun, M.-K.; White, S.W.; Lee, R.E. Synthesis of bi-substrate state mimics of dihydropteroate synthase as potential inhibitors and molecular probes. Bioorganic & Medicinal Chemistry, 2011, 19, 1298-1305.
137. Bourne, C.R.; Bunce, R.A.; Bourne, P.C.; Berlin, K.D.; Barrow, E.W.; Barrow, W.W. Crystal Structure of Bacillus anthracis Dihydrofolate Reductase with the Dihydrophthalazine-Based Trimethoprim Derivative RAB1 Provides a Structural Explanation of Potency and Selectivity. Antimicrob. Agents Chemother., 2009, 53, 3065-3073.
138. Beierlein, J.M.; Frey, K.M.; Bolstad, D.B.; Pelphrey, P.M.; Joska, T.M.; Smith, A.E.; Priestley, N.D.; Wright, D.L.; Anderson, A.C. Synthetic and Crystallographic Studies of a New Inhibitor Series Targeting Bacillus anthracis Dihydrofolate Reductase. Journal of Medicinal Chemistry, 2008, 51, 7532-7540.
139. Hevener, K.E.; Yun, M.-K.; Qi, J.; Kerr, I.D.; Babaoglu, K.; Hurdle, J.G.; Balakrishna, K.; White, S.W.; Lee, R.E. Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. J. Med. Chem., 2010, 53, 166-177.
140. Beierlein, J.M.; Deshmukh, L.; Frey, K.M.; Vinogradova, O.; Anderson, A.C. The Solution Structure of Bacillus anthracis Dihydrofolate Reductase Yields Insight into the Analysis of Structure Activity Relationships for Novel Inhibitors. Biochemistry, 2009, 48, 4100-4108.
141. Bennett, B.C.; Xu, H.; Simmerman, R.F.; Lee, R.E.; Dealwis, C.G. Crystal Structure of the Anthrax Drug Target, Bacillus anthracis Dihydrofolate Reductase. Journal of Medicinal Chemistry, 2007, 50, 4374-4381. (Pubitemid 47378835)
142. Bennett, B.C.; Wan, Q.; Ahmad, M.F.; Langan, P.; Dealwis, C.G. X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: A pharmacophore for dual-site inhibitor design. Journal of Structural Biology, 2009, 166, 162-171.
143. Beierlein, J.M.; Karri, N.G.; Anderson, A.C. Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex. Structure-activity relationships. J. Med. Chem., 2010, 53, 7327-7336.
144. Barrow, E.W.; Dreier, J.; Reinelt, S.; Bourne, P.C.; Barrow, W.W. In vitro Efficacy of New Antifolates against Trimethoprim-Resistant Bacillus anthracis. Antimicrob. Agents Chemother., 2007, 51, 4447-4452. (Pubitemid 350209901)
145. Dreier, J.; Barrow, W.; Barrow, E. Method for the treatment of anthrax infections. US Patent Application 20100305119, 2010.
146. Whalen, K.L.; Tussey, K.B.; Blanke, S.R.; Spies, M.A., Nature of allosteric inhibition in glutamate racemase: Discovery and characterization of a cryptic inhibitory pocket using atomistic MD simulations and pKa calculations. J. Phys. Chem. B, 2011, 115, 3416-3424.